Cargando…
Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension
BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monot...
Autores principales: | Kim, Jae Hyun, Kim, Jung Min, Cho, Youn Zoo, Na, Ji Hoon, Kim, Hyun Sik, Kim, Hyoun A, Kang, Hye Won, Baik, Soon Koo, Kwon, Sang Ok, Cha, Seung Hwan, Kim, Young Ju, Kim, Moon Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association for the Study of the Liver
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278069/ https://www.ncbi.nlm.nih.gov/pubmed/25548744 http://dx.doi.org/10.3350/cmh.2014.20.4.376 |
Ejemplares similares
-
Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study
por: Lim, Yoo Li, et al.
Publicado: (2017) -
The Accuracy of Ultrasonography for the Evaluation of Portal Hypertension in Patients with Cirrhosis: A Systematic Review
por: Kim, Gaeun, et al.
Publicado: (2015) -
Systemic exposure to propranolol in patients with chronic liver disease and its correlation with portal blood flow
por: Kim, Tae-Eun, et al.
Publicado: (2022) -
Clinical Implications of the Serum Apelin Level on Portal Hypertension and Prognosis of Liver Cirrhosis
por: Lim, Yoo Li, et al.
Publicado: (2016) -
Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study
por: Jang, Hye-In, et al.
Publicado: (2017)